Easywell Biomedicals (ROCO:1799) ROCE % : -18.31% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Easywell Biomedicals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Easywell Biomedicals's annualized ROCE % for the quarter that ended in Dec. 2023 was -18.31%.

Easywell Biomedicals ROCE % Historical Data

The historical data trend for Easywell Biomedicals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easywell Biomedicals ROCE % Chart

Easywell Biomedicals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-27.64

-16.10

-13.43

-12.93

-13.73

Easywell Biomedicals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-14.94	-17.89	-8.40	-11.98	-18.31

Easywell Biomedicals ROCE % Calculation

Easywell Biomedicals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-150.651	/	( ( (1173.154 - 64.112)	+	(1213.784 - 127.567) )	/ 2 )
	=	-150.651	/	( (1109.042	+	1086.217)	/ 2 )
	=	-150.651	/	1097.6295
	=	-13.73 %

Easywell Biomedicals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-196.332	/	( ( (1172.071 - 113.553)	+	(1213.784 - 127.567) )	/ 2 )
	=	-196.332	/	( ( 1058.518	+	1086.217 )	/ 2 )
	=	-196.332	/	1072.3675
	=	-18.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Easywell Biomedicals (ROCO:1799) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Easywell Biomedicals ROCE % Related Terms

Thank you for viewing the detailed overview of Easywell Biomedicals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Easywell Biomedicals (ROCO:1799) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Easywell Biomedicals Inc (ROCO:1799) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.10, Yanfa 2nd Rd, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076

Website

http://www.easywellbio.com/en/index.php

Easywell Biomedicals Inc is engaged in the design, manufacture, and sales of thermometers for measuring body temperature and other medical instruments such as digital clinical thermometers, infrared ear thermometers, probe covers, and blood/urine/total cholesterol metabolites monitoring systems, among others. It has a Drug development segment and Other segments.

Easywell Biomedicals (ROCO:1799) Headlines

No Headlines